Supplementary Table S1. Comparison of variables between MPA patients with and without the first-year cumulative MPO-ANCA titres ≥ 60.1 IU/mL.

Variables	MPA patients with the first-year cumulative MPO-ANCA titres <270.8 IU/mL (N=54)	MPA patients with the first-year cumulative MPO-ANCA titres ≥270.8 IU/mL (n=20)	*p*-value
Variables at MPA diagnosis			
Demographic data			
Age (years)	65.5 (18.3)	65.0 (19.8)	0.770
Male gender (N, (%))	17 (31.5)	10 (50.0)	0.142
Ex-smoker (N, (%))	1 (1.9)	1 (5.0)	0.458
BMI (kg/m^2)	22.1 (3.2)	22.2 (5.0)	0.697
Comorbidities (N, (%))			
T2DM	11 (20.4)	7 (35.0)	0.193
Hypertension	21 (38.9)	8 (40.0)	0.931
Dyslipidaemia	8 (14.8)	5 (25.0)	0.307
Clinical features based on BVAS			
General manifestations	25 (46.3)	9 (45.0)	0.921
Cutaneous manifestations	12 (22.2)	1 (5.0)	0.084
Mucous and ocular manifestations	1 (1.9)	1 (5.0)	0.458
Otorhinolaryngologic manifestations	12 (22.2)	7 (35.0)	0.264
Pulmonary manifestations	30 (55.6)	11 (55.0)	0.966
Cardiovascular manifestations	7 (13.0)	0 (0)	0.091
Gastrointestinal manifestations	3 (5.6)	0 (0)	0.282
Renal manifestations	44 (81.5)	14 (70.0)	0.287
Nervous systemic manifestations	13 (24.1)	3 (15.0)	0.400
Variables during MPA follow-up			
Medications (N, (%))			
Glucocorticoids	53 (98.1)	18 (90.0)	0.114
Cyclophosphamide	33 (61.1)	9 (45.0)	0.214
Rituximab	12 (22.2)	3 (15.0)	0.493
Mycophenolate mofetil	18 (33.3)	7 (35.0)	0.893
Azathioprine	39 (72.2)	13 (65.0)	0.546
Tacrolimus	8 (14.8)	1 (5.0)	0.251
Methotrexate	6 (11.1)	1 (5.0)	0.425

Values are expressed as a median (interquartile range, IQR) or N (%).
MPA: microscopic polyangiitis; MPO: myeloperoxidase; ANCA: antineutrophil cytoplasmic antibody; BMI: body mass index; T2DM: type 2 diabetes mellitus; BVAS: Birmingham vasculitis activity score.